Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals,a prospective longitudinal cohort study

PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.     

145例弥漫性大B细胞淋巴瘤患者静脉血栓栓塞发生率及危险因素分析

目的 探讨145例弥漫性大B细胞淋巴瘤(DLBCL)患者静脉血栓栓塞(VTE)发生率及危险因素。方法 选取2016年5月-2019年8月收治的DLBCL患者145例,依据深静脉血栓超声诊断结果分为VTE组(22例)和无VTE组(123例)。采用多因素logistic回归分析DLBCL患者发生VTE的危险因素,及两组复发率、无复发生存率、总体生存率差异。结果 静脉置管、34个疗程化疗未完全缓解(non-CR)、D-二聚体≥1.44 μg/ml是VTE的独立危险因素(OR=5.143、9.000、16.514,P<0.05),体能评分(PS评分) ≥2分为保护因素(OR=0.170,P<0.05);两组复发率、无复发生存率、总体生存率比较差异无统计学意义(P>0.05)。结论 静脉置管、34个疗程化疗non-CR、D-二聚体≥1.44 μg/ml均为DLBCL患者发生VTE的独立危险因素,PS评分≥2分为保护因素。     

Building new standards to prevent harm from medication errors in children with cancer

• Children with cancer receive many medications outside the hospital administered by their caregivers.
• The study by Walsh et al. shows the number and types of medication errors in these patients. The study includes data from three different centers.
• Importantly, the study shows the types of errors that cause harm. The authors describe how the harmful errors can be prevented.
• We suggest ways these results can be used to identify which patients and families will benefit from additional attention. Providing more help at clinic and in the home may help prevent harmful medication errors in children with cancer.

     

婚姻状态对原发性中枢神经系统淋巴瘤患者预后的影响：一项倾向性评分匹配研究

背景 原发性中枢神经系统淋巴瘤（PCNSL）的预后较差，明确其预后危险因素是改善其预后的关键。生物-心理-社会医学模式提示社会心理因素的重要性。婚姻是重要的社会心理因素之一，但婚姻状态对PNSCL患者预后的影响尚不明确。 目的 探究婚姻状态对PCNSL患者总生存（OS）和癌因生存（CSS）的影响。 方法 于2020年，提取2000—2016年美国"监测、流行病学和结果"数据库的3 993例PCNSL患者的病例资料，包括社会人口学资料（婚姻状态、确诊年龄、种族、性别和确诊年份）、临床病理资料（病理类型、肿瘤位置）、治疗资料（手术、放疗和化疗）及结局资料（生存信息和随访时间）。依据婚姻状态将患者分为已婚和非已婚两组，其中非已婚包括单身、离异和丧偶。采用倾向性评分匹配均衡基线资料，采用Kaplan-Meier分析（Log-rank检验）、Cox回归评估婚姻状态对患者OS和CSS的影响。 结果 倾向性评分匹配后，已婚组和非已婚组患者基线资料比较，差异均无统计学意义（P>0.05）。将患者按婚姻状态分为已婚和非已婚组：Log-rank检验结果显示，与已婚患者相比，非已婚患者的OS和CSS更差（P<0.05）；倾向性评分匹配后，校正确诊年龄、种族、性别、确诊年份、病理类型、肿瘤位置、手术、放疗和化疗因素后，多因素Cox回归分析结果显示，非已婚患者的OS风险是已婚患者的1.24倍〔95%CI（1.14，1.36），P<0.001〕，非已婚患者的CSS风险是已婚患者的1.22倍〔95%CI（1.11，1.33），P<0.001〕。将患者按婚姻状态分为已婚、单身、离异、丧偶组：Log-rank检验结果显示，与已婚患者相比，丧偶患者的OS和CSS预后更差（P<0.05）；校正确诊年龄、种族、性别、确诊年份、病理类型、肿瘤位置、手术、放疗和化疗因素后，多因素Cox回归结果显示，单身患者OS和CSS风险分别是已婚患者的1.14倍〔95%CI（1.03，1.27），P=0.013〕和1.15倍〔95%CI（1.03，1.29），P=0.012〕，离异患者OS和CSS风险分别是已婚患者的1.23倍〔95%CI（1.07，1.41），P=0.004〕和1.22倍〔95%CI（1.05，1.41），P=0.009〕，丧偶患者OS和CSS风险分别是已婚患者的1.37倍〔95%CI（1.21，1.54），P<0.001〕和1.28倍〔95%CI（1.12，1.46），P=0.013〕。 结论 婚姻状态影响PCNSL患者OS和CSS，与已婚相比，单身、离异和丧偶患者的预后更差，这提示在临床管理和决策中，除了传统的肿瘤生物学特征，还应关注婚姻状态对PCNSL患者预后的影响。     

New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL/BCL-2 inhibition with navitoclax

Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-X_L) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment.     

Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions

Bromodomain-containing protein 4 (BRD4) is emerging as a therapeutic target that acts synergistically with other targets of small-molecule drugs in cancer. Therefore, the discovery of potential new dual-target inhibitors of BRD4 may be a promising strategy for cancer therapy. In this review, we highlight a series of strategies to design therapeutic dual-target inhibitors of BRD4 that focus on the synergistic functions of this protein. Drug combinations that exploit synthetic lethality, protein–protein interactions, functional complementarity, and blocking of resistance mechanisms could ultimately overcome the barriers inherent to the development of BRD4 inhibitors as future cancer drugs.